DOCSLIB.ORG

Tazarotene Cream for the Treatment of Facial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tazarotene Cream for the Treatment of Facial STUDY Tazarotene Cream for the Treatment of Facial Photodamage A Multicenter, Investigator-Masked, Randomized, Vehicle-Controlled, Parallel Comparison of 0.01%, 0.025%, 0.05%, and 0.1% Tazarotene Creams With 0.05% Tretinoin Emollient Cream Applied Once Daily for 24 Weeks Sewon Kang, MD; James J. Leyden, MD; Nicholas J. Lowe, MD; Jean-Paul Ortonne, MD; Tania J. Phillips, MD; Gerald D. Weinstein, MD; Jag Bhawan, MD; Deborah A. Lew-Kaya, PharmD; Richard M. Matsumoto, PhD; John Sefton, PhD; Patricia S. Walker, MD, PhD; John R. Gibson, MD Objective: To assess the safety and efficacy of 4 con- Results: Tazarotenecreamandtretinoincreamsignificantly centrations of tazarotene cream in the treatment of improved mottled hyperpigmentation and fine wrinkles. facial photodamage. Atweek24,treatmentsuccessratesbasedonglobalresponses were 67% (39 of 58 subjects) with 0.1% tazarotene, 52% Design: Prospective weekly multicenter, investigator- (30 of 58 subjects) with 0.05% tazarotene, 36% (21 of 58 masked, randomized, parallel-group study. subjects) with 0.025% tazarotene, 41% (24 of 59 subjects) with 0.01% tazarotene, 55% (32 of 58 subjects) with 0.05% Setting: University hospitals and clinical research tretinoin, and 22% (13 of 58 subjects) with vehicle. Local centers. adverse events, although more frequent with tazarotene at higher concentrations, were generally mild to moderate. Patients: Three hundred forty-nine subjects with fa- cial photodamage. Conclusions: Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment Intervention: Daily topical application of tazarotene of photodamaged facial skin. cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream. Arch Dermatol. 2001;137:1597-1604 V IRRADIATION from the The topical retinoid tretinoin (all- sun causes premature trans-retinoic acid) has been shown to skin aging, also known as improve fine wrinkles, mottled hyperpig- photoaging. Photoaged mentation, and tactile roughness associ- skin is characterized by ated with photoaged skin.1,4 Histologi- Ucoarse and fine wrinkles, roughness, yel- cally, the improvement in appearance of lowness, laxity, uneven pigmentation, photoaged skin following topical treti- brown spots, and a leathery appearance.1 noin use is associated with compaction In contrast, chronologically aged skin that of the stratum corneum, thickening of has been protected from the sun is thin and the epidermis, reduced melanin content, has reduced elasticity but is otherwise and increased glycosaminoglycans.3,5 The smooth and unblemished.2 effacement of wrinkles correlates with a Histologically, photoaged skin dem- partial restoration of type I procollagen, onstrates an alteration in the dermal ma- which is typically reduced in photodam- trix. Abnormal elastin-containing mate- aged skin.6 rial and a disorganization of collagen fibrils Retinoids like tretinoin and tazaro- are the hallmark signs. In addition, the lev- tene mediate their responses primarily els of types I and III collagen precursors through activation of nuclear retinoid re- are reduced in photoaged skin compared ceptors. There are 2 families of nuclear reti- with sun-protected buttock skin.3 Changes noic acid receptors: the retinoic acid re- The affiliations of the authors in the epidermis can include a decrease in ceptor (RAR) family and the retinoid X appear in the acknowledgement epidermal polarity and an increase in ke- receptor family. Each receptor family con- section at the end of the article. ratinocytic atypia.2 tains 3 receptor subtypes: ␣, ␤, and ␥.7 (REPRINTED) ARCH DERMATOL / VOL 137, DEC 2001 WWW.ARCHDERMATOL.COM 1597 ©2001 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 PARTICIPANTS AND METHODS centers were instructed not to apply the study medication on those evenings before blood sampling. Subjects were ad- STUDY POPULATION vised to avoid excessive sun exposure, to wear protective clothing when exposed to sunlight, and to use a daily sun- Male or female volunteers, 18 years or older, with skin types screen with a sun protective factor of at least 15. I (always burns easily and never tans), II (always burns eas- ily and tans minimally), III (burns moderately and tans gradu- CLINICAL EVALUATIONS ally), or IV (burns minimally and always tans well) and with at least moderate facial photodamage (but otherwise healthy) Evaluations were conducted at a pretreatment screening were eligible for recruitment into this 24-week multicenter visit, at weeks 0 (baseline), 2, 4, 8, 12, 16, 20, and 24, and study. The design was double blinded (with reference to taz- 2 weeks posttreatment (week 26). arotene creams vs vehicle), investigator masked (with ref- erence to the comparison vs tretinoin cream), randomized, EFFICACY MEASURES vehicle controlled, and a parallel comparison. Subjects had to have a baseline facial overall integrated assessment (OIA) Efficacy variables evaluated at all study visits included the of photodamage score of at least 3, on a 6-point scale (0 in- following: fine wrinkling, mottled hyperpigmentation, len- dicates no photodamage; 1, minimal photodamage; 2, mild tigines, irregular depigmentation, tactile roughness, coarse photodamage; 3, moderate photodamage; 4, severe pho- wrinkling, telangiectasia, pore size, elastosis, actinic kera- todamage; and 5, very severe photodamage). In addition, a toses, and OIA of photodamage. The OIA measure encom- baseline severity for either mottled hyperpigmentation or fine passed all the individual signs of photodamage. A pho- wrinkling of at least 3, on a 6-point scale, was required. Ex- tonumeric guideline illustrating the OIA grades of minimal, cluded were any volunteers who had used topical glycolic mild, moderate, and severe (3 examples per severity) was acid, ␣–hydroxy acid, salicylic acid, lactic acid, or ␤–hy- provided to assist the investigators in deriving an accurate droxy acid or vitamin A, ascorbic acid–, or vitamin E–con- and reproducible OIA score. Each of the efficacy variables taining products within 14 days before study enrollment and was evaluated on a 6-point scale (0 indicates none; 1, mini- those who had used topical or systemic retinoids within 6 mal; 2, mild; 3, moderate; 4, severe; and 5, very severe). months before study enrollment. Pregnant and nursing For these evaluations, evaluators did not have to remem- women were excluded, and women of childbearing poten- ber the status of the patient’s condition at baseline. tial were required to use a reliable form of contraception, have Global response to treatment, on the other hand, was a a normal menstrual cycle, and have a negative urine preg- measure that did involve memory. At each visit, evaluators nancy test result at baseline (week 0) and at weeks 4, 8, 12, compared the subject’s condition with that at baseline and 16, 20, and 24. Written informed consent was obtained from expressed the response on a 7-point scale (0 indicates com- all subjects, and the study was conducted in compliance with plete response [100% resolution of photodamage]; 1, al- Good Clinical Practices, Institutional Human Review Board most complete response [approximately 90% improve- Regulations, and the Declaration of Helsinki. Subjects were ment]; 2, marked response [approximately 75% randomly assigned to 1 of the 6 treatment groups using a improvement]; 3, moderate response [approximately 50% im- computerized randomization method. provement]; 4, slight response [approximately 25% improve- ment]; 5, no response; and 6, condition worsened). STUDY MEDICATIONS At the end of the study, subjects were asked for an evaluation of the cosmetic characteristics of the study medi- Study medications evaluated were 0.01%, 0.025%, 0.05%, cation and for a self-assessment of their overall response and 0.1% tazarotene creams, its inactive vehicle cream (Al- to treatment, compared with their condition at baseline, lergan, Inc, Irvine, Calif), and 0.05% tretinoin emollient using the following 5-point scale: 1 indicates much im- cream (Renova; Ortho Pharmaceutical Corp, Raritan, NJ). proved; 2, somewhat improved; 3, no change; 4, some- what worse; and 5, much worse. In addition, subjects were TREATMENTS asked to rate the cosmetic characteristics of the study medi- cation, to indicate whether they would continue to use the Subjects applied the study medication to the face every study medication, and to compare the study medication with evening for 24 weeks. They were instructed to wash and previously used products to treat photodamage. dry their faces before application, and to apply a thin layer of the study medication to lightly cover the face. Facial CRITERION FOR EFFECTIVENESS moisturizers, if used, were to be applied at least 1 hour be- fore or after application of the study medication. Those par- The effectiveness of the test products was deemed clini- ticipating in therapeutic drug monitoring at selected study cally significant if the difference in the proportion of Tretinoin and tazarotene display different receptor se- dermis is RAR ␥.9 It is unknown whether the receptor lectivities. Whereas tretinoin activates the RARs ␣, ␤, and selectivity of tazarotene has any particular clinical sig- ␥ directly, and the retinoid X receptors ␣, ␤, and ␥ in- nificance in the treatment of skin conditions such as pho- directly (through conversion of tretinoin to 9-cis- todamage. retinoic acid8), tazarotenic acid, the metabolite of taz- As an RAR agonist, tazarotene could be effective
Load more

Recommended publications
  • Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems
    pharmaceutics Review Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems Gemma Latter 1, Jeffrey E. Grice 2, Yousuf Mohammed 2 , Michael S. Roberts 2,3 and Heather A. E. Benson 1,* 1 School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6845, Australia; [email protected] 2 Therapeutics Research Group, The University of Queensland Diamantina Institute, School of Medicine, University of Queensland, Translational Research Institute, Brisbane 4109, Australia; jeff[email protected] (J.E.G.); [email protected] (Y.M.); [email protected] (M.S.R.) 3 School of Pharmacy and Medical Sciences, University of South Australia, Basil Hetzel Institute for Translational Health Research, Adelaide 5011, Australia * Correspondence: [email protected]; Tel.: +61-8-9266-2338 Received: 19 August 2019; Accepted: 17 September 2019; Published: 24 September 2019 Abstract: Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% Cream Without Compromising Efficacy in Patients with Acne
    Poster 101 Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% Cream Without Compromising Efficacy in Patients With Acne Vulgaris Emil Tanghetti,1 Zoe Draelos,2 Pearl Grimes,3 Sunil Dhawan,4 Michael Gold,5 Leon Kircik,6 Lawrence Green,7 Angela Moore,8 Fran Cook-Bolden9 1Center for Dermatology and Laser Surgery, Sacramento, CA; 2Dermatology Consulting Services, High Point, NC; 3Vitiligo & Pigmentation Institute of Southern California, Los Angeles, CA; 4Center for Dermatology, Cosmetic and Laser Surgery, Fremont, CA; 5Tennessee Clinical Research Center, Nashville, TN; 6Physicians Skin Care PLLC, Louisville, KY; 7The George Washington University, Washington, DC; 8Arlington Center for Dermatology, Arlington, TX; 9The Skin Specialty Group, New York, NY • 6 months for systemic retinoids Table 1. Scale used to assess overall disease severity. • Mean levels of compliance were between “mostly compliant” and Efficacy Tolerability INTRODUCTION “very compliant” in both groups throughout the study. There were Score Overall disease severity no significant between-group differences in the degree of • The reduction in lesion counts with tazarotene + moisturizer was at • No adverse events considered probably or definitely related to treatment The use of any topical retinoid can involve a period of “retinization” in the first Treatment regimen 0 None—clear, no inflammatory lesions compliance. least as great as that with tazarotene alone at week 16: were reported. few weeks of treatment while the skin is adapting to the retinoid. During this • Patients were randomly assigned (on a 1:2 basis) to one of the following 1 Sparse comedones, with very few or no inflammatory lesions present period of acclimatization, some patients transiently experience dryness, – 57% vs.
    [Show full text]
  • DF Fall 2019-Webready
    A DERMATOLOGY FOUNDATION PUBLICATION SPONSORED BY ORTHO DERMATOLOGICS VOL. 38 NO. 2 FALL 2019 DDEERRMMAATTOOLLOOGGYY ™ Also In This Issue FOCUSFOCUS Janet Fairley, MD, New DF President: “DF support has profoundly advanced our specialty.” DF Clinical Symposia: Stiefel Scholar Cancer Research— Proceedings 2019–Part II Aiming to Normalize KC Cells Explaining that the child’s skin barrier has a structural defect enables ADVANCES IN DERMATOLOGY parents to understand the involvement of inadequate hydration, more bacteria, and increased penetration of antigens and allergens. Then The Dermatology Foundation presented its Maguiness explains the need to simultaneously treat the dehydrated annual 3-day cutting-edge CME symposia series skin, itch, inflammation, and infection, and teaches parents the entire earlier this year. Informal Breakfast Roundtables 2-week topical “eczema boot camp” routine: bleach baths, topical and evening Therapeutics Forums amplified the steroids, emollients, and wet wraps, typically done at home. She reassuringly likens a bleach bath to a swimming pool. Maguiness take-home value. Part II of the Proceedings includes described the procedures and benefits of bleach baths and wet wraps Therapeutic Updates; Diagnostic Dilemmas; and in detail, provided practical tips for gaining parental confidence and Medical Dermatology. (Part I, which appeared understanding, noted variations to the overall “boot camp” routine, and in the previous issue, included the Keynote talk discussed tapering. Then she shared her excitement about “entering
    [Show full text]
  • Pathway Development Via Retinoid X Receptor Vitamin a Enhances In
    Vitamin A Enhances in Vitro Th2 Development Via Retinoid X Receptor Pathway This information is current as Charles B. Stephensen, Reuven Rasooly, Xiaowen Jiang, of September 24, 2021. Michael A. Ceddia, Casey T. Weaver, Roshantha A. S. Chandraratna and R. Patterson Bucy J Immunol 2002; 168:4495-4503; ; doi: 10.4049/jimmunol.168.9.4495 http://www.jimmunol.org/content/168/9/4495 Downloaded from References This article cites 40 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/168/9/4495.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Vitamin A Enhances in Vitro Th2 Development Via Retinoid X Receptor Pathway1 Charles B. Stephensen,2* Reuven Rasooly,* Xiaowen Jiang,* Michael A. Ceddia,3* Casey T. Weaver,† Roshantha A. S. Chandraratna,‡ and R. Patterson Bucy† Vitamin A deficiency diminishes Th2-mediated Ab responses, and high-level dietary vitamin A or treatment with the vitamin A metabolite retinoic acid (RA) enhances such responses.
    [Show full text]
  • TAZORAC® (Tazarotene) Gel 0.05% (Tazarotene) Gel 0.1%
    NDA 020600 ® TAZORAC (tazarotene) Gel 0.05% (tazarotene) Gel 0.1% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE DESCRIPTION TAZORAC® Gel is a translucent, aqueous gel and contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical dermatologic use only. The active ingredient is represented by the following structural formula: O OCH2CH3 N S TAZAROTENE C21H21NO2S Molecular Weight: 351.46 Chemical Name: Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate Contains: Active: Tazarotene 0.05% or 0.1% (w/w) Preservative: Benzyl alcohol 1% (w/w) Inactives: Ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, carbomer 934P, edetate disodium, hexylene glycol, poloxamer 407, polyethylene glycol 400, polysorbate 40, purified water, and tromethamine. CLINICAL PHARMACOLOGY Tazarotene is a retinoid prodrug which is converted to its active form, the cognate carboxylic acid of tazarotene (AGN 190299), by rapid deesterification in animals and man. AGN 190299 (“tazarotenic acid”) binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings is unknown. Psoriasis: The mechanism of tazarotene action in psoriasis is not defined. Topical tazarotene blocks induction of mouse epidermal ornithine decarboxylase (ODC) activity, which is associated with cell proliferation and hyperplasia. In cell culture and in vitro models of skin, tazarotene suppresses expression of MRP8, a marker of inflammation present in the epidermis of psoriasis patients at high levels. In human keratinocyte cultures, it inhibits cornified envelope formation, whose build-up is an element of the psoriatic scale.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Tazarotene Topical Gel 0.1%
    Contains Nonbinding Recommendations Draft Guidance on Tazarotene This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Tazarotene Dosage Form; Route: Gel; topical Recommended Studies: One study Type of study: Bioequivalence study with clinical endpoint Design: Randomized, double blind, parallel, placebo controlled, in vivo Strength: 0.1% Subjects: Males and nonpregnant, nonlactating females with acne vulgaris Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (90% CI): Clinical endpoint Waiver request of in vivo testing: Not applicable Dissolution test method and sampling times: Not applicable Applicants intending to propose an alternative approach by which to demonstrate bioequivalence should refer to the guidance for industry Controlled Correspondence Related to Generic Drug Development and the guidance for industry Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA for additional information describing the procedures on how to clarify regulatory expectations regarding your individual drug development program. Additional comments regarding the bioequivalence study with clinical endpoint: 1. The Office of Generic Drugs recommends conducting a single bioequivalence study with clinical endpoint in the treatment of acne vulgaris comparing the tazarotene topical gel, 0.1% test product versus the reference product and placebo control, each applied once daily in the evening for 12 weeks.
    [Show full text]
  • Oxidation of Retinol to Retinoic Acid As a Requirement for Biological Activity in Mouse Epidermis1
    [CANCER RESEARCH 48, 7038-7040, December 15, 1988] Oxidation of Retinol to Retinoic Acid as a Requirement for Biological Activity in Mouse Epidermis1 Michael J. Connor Division of Dermatology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024 ABSTRACT of retinal, which may explain its ability to inhibit both steps in The food and fragrance additive citral (3,7-dimethyl-2,6-octadienal) retinoic acid synthesis from retinol, since as an aldehyde it can inhibits the oxidation of retino! to retinole acid in mouse epidermis on act as a substrate for both the alcohol- and aldehyde-dehydro- local application. This inhibitory property was used to test the hypothesis genases involved. that oxidation to retinole acid is rate limiting for the biological activity The ability of citral to inhibit retinol oxidation provides an of vitamin A (retinol) in epithelial tissues. Citral was tested as a modulator experimental tool for testing the paradigm that retinoic acid is of the biological activities of retinol and retinole acid using two bioassays an obligatory intermediate in at least some aspects of vitamin performed in Skh.hrI (hairless) mice: (a) the ability to induce epidermal A activity in the epithelia in vivo. Citral was proposed as a hyperplasia; (/>)the ability to inhibit the induction of epidermal ornithine vitamin A antagonist in 1956 (7). Aydelotte (8, 9) studied the decarboxylase activity by tumor promoters. Citral treatment inhibited interaction of citral and retinol in whole organ cultures of chick the ability of retinol, but not of retinoic acid, to induce epidermal epithelial tissues and concluded that citral had a competitive hyperplasia.
    [Show full text]
  • 1 EMA Tender EMA/2017/09/PE, Lot 2 Impact of EU Label
    EMA tender EMA/2017/09/PE, Lot 2 Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence Protocol • Prof. Anna Birna Almarsdóttir, Professor in Social and Clinical Pharmacy at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen • Prof. Marcel Bouvy, Professor of Pharmaceutical Care at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Rob Heerdink, Associate Professor at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Teresa Leonardo Alves, Researcher at the Centre for Health Protection, National Institute for Public Health and the Environment, The Netherlands. 1 Table of contents Background ...................................................................................................................... 3 Aims of the study ............................................................................................................. 4 Methods ........................................................................................................................... 4 Setting ........................................................................................... Error! Bookmark not defined. Study design ............................................................................................................................ 4 Population
    [Show full text]
  • Isotretinoin (Accutane) and Pregnancy
    Isotretinoin (Accutane®) This sheet talks about exposure to isotretinoin in a pregnancy or while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is isotretinoin? Isotretinoin is a prescription medication taken by mouth to treat severe cystic acne that has not responded to other treatments. Isotretinoin is a form of Vitamin A. It has been sold under brand names such as Accutane®, Absorica®, Amnesteem®, Claravis®, Epuris®, Clarus®, Myorisan®, Sotret®, and Zenatane®. How long after a woman stops taking isotretinoin should she wait to become pregnant? How long does isotretinoin stay in the body? It is recommended that a woman wait one month after stopping isotretinoin before trying to become pregnant. Usually, isotretinoin is no longer found in a woman’s blood 4-5 days after the last dose and most of its by-products should be gone within 10 days after the last dose. However, the time it takes isotretinoin to be cleared from the body can be longer in some people, which is why it is recommended to wait at least one month after stopping isotretinoin before trying to become pregnant. Can isotretinoin make it more difficult to get pregnant? Women who are trying to become pregnant should not be taking isotretinoin. There have been reports of irregular menstrual periods in some women taking isotretinoin. There are no reports of problems getting pregnant while taking isotretinoin. I just found out I am pregnant. Should I stop taking isotretinoin? Stop taking the medication right away. As soon as possible, call the healthcare provider who prescribed the isotretinoin and the healthcare provider who will be taking care of you during your pregnancy.
    [Show full text]
  • Isotretinoin for Neuroblastoma
    Isotretinoin for Neuroblastoma Isotretinoin (EYE so TRET in oin) is a form of vitamin A that is very concentrated. It can only be obtained by prescription. The oily liquid comes in a soft capsule. Brand names for this medicine are Amnesteem®, Absorica®, Claravis®, Myorisan® and Zenatane®. Isotretinoin is used to treat neuroblastoma, the most common type of cancer in children. This medicine is given along with other immunotherapy (cancer fighting) drugs during the active stage of illness. It may also be ordered to be taken during the maintenance phase of therapy. Usually isotretinoin is given after the child has received the medicine 131I- Metaiodobenzylguanidine (MIBG) and has had a Bone Marrow Transplant (BMT). Warnings If your child is allergic to retinoids, he should not take this medicine. When handling this drug, extreme care needs to be followed by women who are pregnant or breastfeeding. Isotretinoin can cause severe birth defects and can pass into breast milk. Someone else will need to give this medicine to your child. Because of the dangers of birth defects with isotretinoin, your child, your child’s doctor, and your pharmacy must register with the iPLEDGE™ program. To do this, go to www.ipledgeprogram.com. Failure to register means that your child will not get the medicine. When your child needs more medicine, the doctor will have to write a new prescription each time. How to give Isotretinoin can be given by mouth whole, buried in food whole, or dissolved and mixed with food. Always wear disposable gloves if there is a risk of touching the liquid inside the capsule.
    [Show full text]